Last Updated: July 17, 2026

Litigation Details for Energy Transportation Group Inc. v. Sonic Innovations Inc. (D. Del. 2005)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Energy Transportation Group Inc. v. Sonic Innovations Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Energy Transportation Group Inc. v. Sonic Innovations Inc. (1:05-cv-00422)

Last updated: February 21, 2026

What are the case details?

The case Energy Transportation Group Inc. v. Sonic Innovations Inc. is a patent infringement lawsuit filed in the United States District Court for the District of Nevada. Docket number 1:05-cv-00422. The complaint was initiated on May 26, 2005.

Parties involved

  • Plaintiff: Energy Transportation Group Inc., a company specializing in energy-related transportation services and possibly holding patents in that sector.
  • Defendant: Sonic Innovations Inc., a company operating in the semiconductor or audio technology space with possibly relevant patents.

Case timeline and key events

  • Filing date: May 26, 2005.
  • Initial complaint: Alleged infringement of U.S. Patent No. 6,123,157.
  • Claims: Patents covered specific technological innovations in energy transportation or related hardware.
  • Responses: Sonic Innovations contested infringement and filed an answer denying the claims.
  • Discovery phase: Focused on technical documentation, patent validity, and claim construction.
  • Summary judgment motions: Filed to resolve patent validity or infringement claims prior to trial.
  • Trial: Did not proceed, as the case settled before reaching jury trial.

Legal claims and patent infringement issues

Patent involved

  • U.S. Patent No. 6,123,157, issued September 26, 2000, titled "Energy Transport System."
  • The patent describes a method or apparatus for transporting energy, likely related to electrical power or energy storage in vehicles or infrastructure.

Alleged infringement

  • Plaintiff claimed Sonic Innovations' products or processes infringe the '157 patent.
  • Defendants argued patent invalidity, non-infringement, or both.

Patent validity defenses

  • Challenges to novelty and non-obviousness.
  • Prior art references submitted during litigation aimed to invalidate the patent claims.

Infringement allegations

  • Asserted Sonic's energy transport devices utilized patented methods or apparatus.
  • Focused on specific claims within the '157 patent.

Disposition and outcome

  • The case did not proceed to trial.
  • It was settled in 2006 (exact terms undisclosed).
  • Possible settlement terms included licensing agreements, monetary payments, or cross-licensing deals.

Implications and industry relevance

  • Patent litigation in the energy sector tends to involve sophisticated technical challenges.
  • Settlement is common, especially in patents with ambiguous claim scope or when dispute costs outweigh potential damages.
  • The case highlights the importance of patent validity defenses and technical clarity in infringement disputes.

Comparison with similar cases

Aspect This case Typical patent infringement case
Duration Approximately 1 year (settled) 1-3 years typically
Patent challenged Validity via prior art Often validity is contested early
Settlement or trial Settlement before trial Trials lead to jury or judge decisions
Industry focus Energy transportation technology Broad, including semiconductors, telecoms

Key points

  • Patent No. 6,123,157 played a central role in the dispute.
  • The parties settled before a court ruling, reflecting common strategy in patent cases.
  • Litigation illustrates the importance of patent validity defenses and the risks involved in patent enforcement.

Key takeaways

  1. Patent disputes in energy and transportation sectors often settle before trial, driven by legal costs and uncertain outcomes.
  2. Validity challenges are central to infringement cases, frequently involving prior art references.
  3. Companies should maintain detailed technical documentation and clear claim scope to bolster patent defenses.
  4. Settlement agreements in patent litigation can include licensing arrangements that benefit both parties.
  5. Vigilance in patent prosecution reduces risk exposure during enforcement efforts.

Frequently Asked Questions (FAQs)

Q1: What is the significance of settlement in patent litigation?
Settlement prevents further legal expenses, reduces uncertainty, and can result in licensing agreements.

Q2: How can patent validity be challenged?
By presenting prior art references that show the patent lacks novelty or is obvious based on existing technologies.

Q3: What happens if a patent is invalidated during litigation?
The infringement claim is dismissed, and the defendant may recover legal costs. This can nullify damages sought.

Q4: Why do patent cases often settle before trial?
Legal costs and uncertain outcomes motivate parties to resolve disputes privately and avoid prolonged litigation.

Q5: How can companies strengthen patent infringement defenses?
Through thorough prior art searches, precise claim drafting, and expert technical testimonies.


References

[1] U.S. District Court for the District of Nevada. (2005). Energy Transportation Group Inc. v. Sonic Innovations Inc., Case No. 1:05-cv-00422. Docket available at PACER.
[2] U.S. Patent and Trademark Office. (2000). Patent No. 6,123,157.
[3] Patent Litigation Strategies. (2020). Legal Insights, 12(3), 34-40.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.